A Phase 2/3 Age De-escalating Study to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Vaccine (SARS-CoV-2 rS) with Matrix-M™ Adjuvant in Children 6 months to < 12 years of age
Overview
Morehouse School of Medicine is participating in a new clinical trial called the HUMMINGBIRD study, a Phase 2/3 study to evaluate the safety and immunogenicity of an investigational vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in pediatric participants.
Is it free to participate in a study?
There will be no charge to study participants for their participation in this study. The investigational vaccine and placebo, study-related procedures, and study visits will be provided at no charge. Study transportation may be provided (based on availability), and participants will be compensated for time and study-related travel.
Who can participate?
Participants must be 6 months to < 12 years of age
Be healthy or medically stable
Should not have prior administration of a coronavirus vaccine or previous lab-confirmed diagnosis of SARS-CoV-2 infection or COVID-19
HUMMINGBIRD study enrollment is currently active, and visits are conducted at Clinical Research Center at Morehouse School of Medicine.
Principal Investigator:
Point of Contact: